[ Synthesis route intelligence ]
Accelerating synthesis route decisions.
Mycelium helps chemistry teams evaluate and prioritise synthesis routes faster, bringing the signals that matter into one clearer decision.
Early access · Prototype in development
Route A
92%
Route B
74%
Evaluating
Preferred route: Route A carries higher confidence, lower complexity and lower cost than Route B.
What if choosing the next synthesis route was easier?
Mycelium is being built to help chemistry teams evaluate synthesis routes continuously, bringing scientific evidence, route complexity and practical considerations together so teams can focus on making the right decision.
The data exists.
The decision still takes time.
Chemistry teams already have scientific data, route information, project knowledge and experimental results, along with the criteria they use to judge one route against another.
Teams spend valuable time collecting, comparing and evaluating this information before they can answer a simple question: what should we make next?
Experimental results scattered across notebooks and reports.
Manual evaluation
Hours, not minutes.
Decision
Finally, a route to pursue.
[ The opportunity ]
Turn continuous evaluation into a better decision.
Mycelium brings the relevant signals together and continuously evaluates candidate routes against agreed criteria, surfacing the evidence that matters when it matters.
Pulling together data, routes and context from scattered sources.
Continuously scores every candidate route against the agreed criteria.
One fewer step between evidence arriving and the route being chosen.
[ The approach ] · [ 03 ]
From evaluating routes to understanding which one matters.
Mycelium continuously evaluates candidate routes against the criteria a project agrees on: pharmacology, ADME & safety, and synthetic and route factors, so the recommendation reflects the full picture.
How well a compound does its job: the starting point for any route decision.
Continuous evaluation → Clearer prioritisation → Faster decisions
Built by people who understand the workflow.
Mycelium is being built within o2h discovery's chemistry practice, led by the team below.
Sunil Shah
Serial entrepreneur in life sciences and technology; co-founded o2h Ventures.
Prashant Shah
Serial entrepreneur in life sciences and tech, active in seed investing across roughly 50 companies.
Andy Morley
25+ years as a medicinal chemist at Sanofi-Aventis and AstraZeneca; author of 55+ publications and patents.
Nilesh Dagia
Leads global operations across o2h's investment, life-science and technology businesses.
Early access
Be part of the next synthesis decision.
Mycelium is being built for teams that want to spend less time assembling the decision and more time making it. Join the waitlist to be notified as the product develops.